BioMarin Pharmaceutical's market cap is currently ―. The company's EPS TTM is $1.069; its P/E ratio is 75.65; BioMarin Pharmaceutical is scheduled to report earnings on July 30, 2024, and the estimated EPS forecast is $0.34. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Income Statement	-
Total Revenue	$ 648.83M	$ 646.21M	$ 581.33M	$ 584.70M	$ 596.41M
Gross Profit	$ 523.65M	$ 510.73M	$ 456.58M	$ 482.82M	$ 454.20M
EBIT	$ 109.09M	$ 25.43M	$ 45.45M	$ 74.56M	$ 60.46M
EBITDA	$ 134.93M	$ 50.83M	$ 70.03M	$ 98.45M	$ 85.94M
Net Income Common Stockholders	$ 88.66M	$ 20.38M	$ 71.74M	$ 56.04M	$ 50.85M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 1.05B	$ 1.07B	$ 1.13B	$ 1.17B	$ 1.15B
Total Assets	$ 6.87B	$ 6.84B	$ 6.76B	$ 6.56B	$ 6.43B
Total Debt	$ 1.09B	$ 1.09B	$ 1.09B	$ 1.08B	$ 1.08B
Net Debt	$ 41.38M	$ 13.16M	$ -39.86M	$ -85.96M	$ -68.08M
Total Liabilities	$ 1.80B	$ 1.89B	$ 1.86B	$ 1.78B	$ 1.77B
Stockholders Equity	$ 5.07B	$ 4.95B	$ 4.90B	$ 4.78B	$ 4.66B
Cash Flow	-
Free Cash Flow	$ 12.87M	$ -9.21M	$ 112.23M	$ 47.38M	$ -98.75M
Operating Cash Flow	$ 46.97M	$ 27.48M	$ 135.65M	$ 70.11M	$ -73.98M
Investing Cash Flow	$ -14.24M	$ -64.96M	$ -45.80M	$ 29.53M	$ -30.01M
Financing Cash Flow	$ -42.79M	$ 10.84M	$ -788.00K	$ 11.96M	$ -40.74M

Currency in USD

BioMarin Pharmaceutical Earnings and Revenue History

Income Statement >

BioMarin Pharmaceutical Debt to Assets

Balance Sheet >

BioMarin Pharmaceutical Cash Flow

Cash Flow >

BioMarin Pharmaceutical Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing